Hematologic response to vorinostat treatment in relapsed myeloid leukemia of Down syndrome
Children with Down syndrome are at high risk to develop myeloid leukemia (ML-DS). Despite their excellent prognosis, children with ML-DS particularly suffer from severe therapy-related toxicities and for relapsed ML-DS the cure rates are very poor. Here we report the clinical course of one child wit...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
18 May 2016
|
| In: |
Pediatric blood & cancer
Year: 2016, Jahrgang: 63, Heft: 9, Pages: 1677-1679 |
| ISSN: | 1545-5017 |
| DOI: | 10.1002/pbc.26062 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1002/pbc.26062 Verlag, Volltext: http://onlinelibrary.wiley.com/doi/10.1002/pbc.26062/abstract 
|
| Verfasserangaben: | Carina Scheer, Christian Kratz, Olaf Witt, Ursula Creutzig, Dirk Reinhardt, and Jan-Henning Klusmann |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1570331790 | ||
| 003 | DE-627 | ||
| 005 | 20230428184811.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180301s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/pbc.26062 |2 doi | |
| 035 | |a (DE-627)1570331790 | ||
| 035 | |a (DE-576)500331790 | ||
| 035 | |a (DE-599)BSZ500331790 | ||
| 035 | |a (OCoLC)1340992777 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Scheer, Carina |e VerfasserIn |0 (DE-588)1153579006 |0 (DE-627)1015100058 |0 (DE-576)500330301 |4 aut | |
| 245 | 1 | 0 | |a Hematologic response to vorinostat treatment in relapsed myeloid leukemia of Down syndrome |c Carina Scheer, Christian Kratz, Olaf Witt, Ursula Creutzig, Dirk Reinhardt, and Jan-Henning Klusmann |
| 264 | 1 | |c 18 May 2016 | |
| 300 | |a 3 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 01.03.2018 | ||
| 520 | |a Children with Down syndrome are at high risk to develop myeloid leukemia (ML-DS). Despite their excellent prognosis, children with ML-DS particularly suffer from severe therapy-related toxicities and for relapsed ML-DS the cure rates are very poor. Here we report the clinical course of one child with ML-DS treated with the histone deacetylase (HDAC) inhibitor vorinostat (suberoylanilide hydroxamic acid) after second relapse. The child had previously received conventional chemotherapy and stem cell transplantation, yet showed a remarkable clinical and hematologic response. Thus, HDAC inhibitor may represent an effective class of drugs for the treatment of ML-DS. | ||
| 650 | 4 | |a AML | |
| 650 | 4 | |a Down syndrome | |
| 650 | 4 | |a HDAC | |
| 650 | 4 | |a HDACi | |
| 650 | 4 | |a histone deacetylase inhibitor | |
| 650 | 4 | |a ML-DS | |
| 650 | 4 | |a vorinostat | |
| 700 | 1 | |a Witt, Olaf |d 1965- |e VerfasserIn |0 (DE-588)17275030X |0 (DE-627)697681750 |0 (DE-576)133607410 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pediatric blood & cancer |d New York, NY : Wiley, 2004 |g 63(2016), 9, Seite 1677-1679 |h Online-Ressource |w (DE-627)37682798X |w (DE-600)2130978-4 |w (DE-576)11281610X |x 1545-5017 |7 nnas |a Hematologic response to vorinostat treatment in relapsed myeloid leukemia of Down syndrome |
| 773 | 1 | 8 | |g volume:63 |g year:2016 |g number:9 |g pages:1677-1679 |g extent:3 |a Hematologic response to vorinostat treatment in relapsed myeloid leukemia of Down syndrome |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/pbc.26062 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://onlinelibrary.wiley.com/doi/10.1002/pbc.26062/abstract |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180301 | ||
| 993 | |a Article | ||
| 994 | |a 2016 | ||
| 998 | |g 17275030X |a Witt, Olaf |m 17275030X:Witt, Olaf |d 910000 |d 910500 |e 910000PW17275030X |e 910500PW17275030X |k 0/910000/ |k 1/910000/910500/ |p 3 | ||
| 999 | |a KXP-PPN1570331790 |e 3001274891 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"physDesc":[{"extent":"3 S."}],"title":[{"title_sort":"Hematologic response to vorinostat treatment in relapsed myeloid leukemia of Down syndrome","title":"Hematologic response to vorinostat treatment in relapsed myeloid leukemia of Down syndrome"}],"relHost":[{"pubHistory":["42.2004 -"],"note":["Gesehen am 13.05.14"],"titleAlt":[{"title":"Pediatric blood and cancer"}],"language":["eng"],"id":{"issn":["1545-5017"],"zdb":["2130978-4"],"eki":["37682798X"],"doi":["10.1002/(ISSN)1545-5017"]},"recId":"37682798X","type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"Hematologic response to vorinostat treatment in relapsed myeloid leukemia of Down syndromePediatric blood & cancer","origin":[{"publisher":"Wiley","dateIssuedDisp":"2004-","dateIssuedKey":"2004","publisherPlace":"New York, NY"}],"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"Pediatric blood & cancer","title":"Pediatric blood & cancer"}],"part":{"extent":"3","pages":"1677-1679","year":"2016","issue":"9","text":"63(2016), 9, Seite 1677-1679","volume":"63"}}],"person":[{"given":"Carina","role":"aut","family":"Scheer","display":"Scheer, Carina"},{"family":"Witt","role":"aut","display":"Witt, Olaf","given":"Olaf"}],"note":["Gesehen am 01.03.2018"],"language":["eng"],"name":{"displayForm":["Carina Scheer, Christian Kratz, Olaf Witt, Ursula Creutzig, Dirk Reinhardt, and Jan-Henning Klusmann"]},"origin":[{"dateIssuedDisp":"18 May 2016","dateIssuedKey":"2016"}],"id":{"eki":["1570331790"],"doi":["10.1002/pbc.26062"]},"recId":"1570331790","type":{"bibl":"article-journal","media":"Online-Ressource"}} | ||
| SRT | |a SCHEERCARIHEMATOLOGI1820 | ||